|
- Bing News Quiz Answers: July 4, 2025 - TellUsTheAnswer
Question 6: Which drug combination showed superior results in a leukemia trial? Ibrutinib and Venetoclax Ibrutinib and Methotrexate Cisplatin and Paclitaxel Answer: Ibrutinib and Venetoclax Fact: The FLAIR trial demonstrated that the combination of Ibrutinib and Venetoclax significantly outperformed traditional chemotherapy in treating chronic lymphocytic leukemia Patients showed higher
- Olverembatinib combined with venetoclax and reduced-intensity . . .
Hence, we carried out a prospective clinical trial to explore the efficacy and safety of olverembatinib combined with venetoclax and reduced-intensity chemotherapy as frontline treatment in Ph+ ALL
- ‘Blin’-ing Is Winning for Children With B-Cell Acute Lymphoblastic Leukemia
Blinatumomab was previously reported to be both safe and effective in children and adolescents young adults with R R B-ALL 10 - 12 In comparison to standard relapse chemotherapy alone, blinatumomab demonstrated superior results in two separate randomized phase Ill clinical trials for pediatric patients with first relapse of B-ALL
- Study Demonstrates Drug Combination Is Well Tolerated, Safe and . . .
Study outcomes showed that the drug combination helped shrink or eliminate cancer in 61% of patients, with 47% having no detectable cancer Eleven patients went on to receive stem cell transplants Additionally, in patients with the nodal T-follicular helper cell subtype of lymphoma, 82% of patients responded well
- Ibrutinib plus rituximab superior to standard treatment for some . . .
An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously untreated chronic lymphocytic leukemia (CLL)
- Combination of approved drugs offers new strategies for acute myeloid . . .
The combined use of two well-known active substances can fight leukemic cells and limit their spread This is the result of a study conducted by the Karl Landsteiner University of Health Sciences
- Survey of ex vivo drug combination effects in chronic lymphocytic . . .
To improve current approaches to combination treatment of chronic lymphocytic leukemia (CLL) and gain insights into the underlying biology, we studied the effect of 352 drug combination pairs in multiple concentrations by analysing ex vivo drug response of 52 primary CLL samples, which were characterized by “omics” profiling
- New Drug Dramatically Improves Survival for Children with Common Type . . .
Bentley McMinn, who was diagnosed with leukemia in 2019, was successfully treated on a clinical trial that studied the effectiveness of a drug-chemotherapy treatment combination
|
|
|